Faricimab has been approved in Europe for treating macular edema due to retinal vein occlusion. The manufacturer did not provide suitable data to show an added benefit of faricimab over other therapies in a recent assessment. Studies comparing faricimab and aflibercept did not adhere to treatment guidelines, making them unsuitable for the assessment. Treatment regimens in the studies did not allow for individual dosing adjustments, leading to continued treatment, even if findings were stable. In contrast, a study on brolucizumab for macular degeneration used a treat-and-extend regimen, allowing for individualized treatment intervals based on disease activity.
Source link
Added benefit of faricimab for macular degeneration not proven by manufacturer
